Quinapril——一个临床前药理学的审查,药物动力学和毒理学。
文章的细节
-
引用
复制到剪贴板 -
卡普兰人力资源,泰勒DG,奥尔森SC,安德鲁斯路
Quinapril——一个临床前药理学的审查,药物动力学和毒理学。
血管学。1989年4月,40 (4 Pt 2): 335 - 50。doi: 10.1177 / 000331978904000403。
- PubMed ID
-
2539761 (在PubMed]
- 文摘
-
Quinapril是一个口服有效,non-peptide nonsulfhydryl血管紧张素转换酶(ACE)抑制剂,徒有说服力地专门阻断血管紧张素I转换血管紧张素ⅱ在血浆和组织。Quinapril是药物活性二酸酶水解quinaprilat形式。Quinapril是有效的高血压模型表现出高(肾高血压大鼠,diuretic-treated狗)和正常的自发性高血压大鼠血浆肾素活性。Quinapril不预防高血压的发展,当血浆肾素活性(PRA)显著抑制deoxycorticosterone-saline治疗鼠。狗血流动力学研究表明,quinapril总外围和肾血管阻力降低。Quinaprilat产生尿钠排泄和轻度利尿剂量不改变平均动脉血压。Quinapril有潜力影响血浆脂质实益,或者至少是“脂质中性的。”Oral absorption of quinapril is rapid in rats, dogs, and monkeys. There is rapid and extensive distribution of radiolabel to most tissues except brain. Plasma radiolabel concentration-time profiles exhibit polyexponential decay with a prolonged terminal phase at low concentrations in all species. Metabolism to compounds other than quinaprilat is not extensive. Quinapril is excreted primarily as quinaprilat and to a lesser degree as quinapril. Quinapril is well tolerated in a variety of pharmacologic safety screens and its toxicity profile is similar to that of other ACE inhibitors. Quinapril does not adversely affect reproduction; it is not teratogenic, carcinogenic, or mutagenic.(ABSTRACT TRUNCATED AT 250 WORDS)
beplay体育安全吗DrugBank数据引用了这篇文章
- 药物
- 药物反应
-
反应 细节
